Why Bargain-Priced Viatris Could Deliver Strong Returns
Viatris is a pharmaceutical company with a diverse portfolio of branded drugs, generics, and biosimilars. It reported strong Q2 2024 performance with operational revenue growth, adjusted EBITDA, and EPS growth, while paying down debt and guiding for continued growth. Viatris offers a 4.2% dividend yield, with potential for future dividend increases and share buybacks, making it an attractive opportunity for income and value investors.
Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis.
Why Viatris Stock Is Jumping Today
Viatris reported Q2 revenue in line with Wall Street expectations. The healthcare company's Q2 adjusted earnings per share topped estimates.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Viatris (VTRS) Q2 Earnings Surpass Estimates
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago.
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
Drugmaker Viatris beat second-quarter profit and revenue estimates on Thursday, driven by strong demand for the Viagra-maker's off-patent branded and generic drugs.
Seeking Clues to Viatris (VTRS) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Viatris (VTRS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2024.
Earnings Preview: Viatris (VTRS) Q2 Earnings Expected to Decline
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US DOJ drops Viatris unit Mylan from industry-wide antitrust probe
Viatris said on Tuesday that its unit Mylan is no longer a subject of the U.S. Department of Justice's antitrust investigation into alleged price fixing in the generic drug industry.
Viatris Inc. (VTRS) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024 9:20 AM ET Company Participants Scott Smith - CEO Theodora Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Why don't we get started?
Viatris Inc. (VTRS) Presents at Jefferies 2024 Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Jefferies 2024 Global Healthcare Conference Call June 6, 2024 8:00 AM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Philippe Martin - Chief R&D Officer Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo All right. Well, good morning, everybody.
